nodes	percent_of_prediction	percent_of_DWPC	metapath
Ipratropium bromide—CYP2D6—breast cancer	0.182	0.538	CbGaD
Ipratropium bromide—CYP3A4—breast cancer	0.156	0.462	CbGaD
Ipratropium bromide—CYP3A4—Exemestane—breast cancer	0.0351	0.103	CbGbCtD
Ipratropium bromide—CYP2D6—Idarubicin—breast cancer	0.0317	0.093	CbGbCtD
Ipratropium bromide—CYP3A4—Letrozole—breast cancer	0.0298	0.0876	CbGbCtD
Ipratropium bromide—CYP3A4—Anastrozole—breast cancer	0.0266	0.0781	CbGbCtD
Ipratropium bromide—CYP3A4—Toremifene—breast cancer	0.0243	0.0714	CbGbCtD
Ipratropium bromide—CYP3A4—Fulvestrant—breast cancer	0.0226	0.0664	CbGbCtD
Ipratropium bromide—CYP3A4—Thiotepa—breast cancer	0.0202	0.0592	CbGbCtD
Ipratropium bromide—CYP3A4—Ixabepilone—breast cancer	0.0184	0.0541	CbGbCtD
Ipratropium bromide—CYP3A4—Lapatinib—breast cancer	0.0177	0.0521	CbGbCtD
Ipratropium bromide—CYP2D6—Vinorelbine—breast cancer	0.0155	0.0454	CbGbCtD
Ipratropium bromide—CYP2D6—Tamoxifen—breast cancer	0.014	0.041	CbGbCtD
Ipratropium bromide—CYP3A4—Raloxifene—breast cancer	0.0135	0.0395	CbGbCtD
Ipratropium bromide—CYP3A4—Vinorelbine—breast cancer	0.00985	0.0289	CbGbCtD
Ipratropium bromide—CYP2D6—Vinblastine—breast cancer	0.00954	0.028	CbGbCtD
Ipratropium bromide—CYP3A4—Tamoxifen—breast cancer	0.00889	0.0261	CbGbCtD
Ipratropium bromide—CYP3A4—Mitoxantrone—breast cancer	0.00867	0.0254	CbGbCtD
Ipratropium bromide—CYP3A4—Paclitaxel—breast cancer	0.00692	0.0203	CbGbCtD
Ipratropium bromide—CYP3A4—Irinotecan—breast cancer	0.00682	0.02	CbGbCtD
Ipratropium bromide—CYP3A4—Vinblastine—breast cancer	0.00607	0.0178	CbGbCtD
Ipratropium bromide—CYP2D6—Doxorubicin—breast cancer	0.00586	0.0172	CbGbCtD
Ipratropium bromide—CHRM3—muscle of abdomen—breast cancer	0.00526	0.237	CbGeAlD
Ipratropium bromide—CYP3A4—Docetaxel—breast cancer	0.005	0.0147	CbGbCtD
Ipratropium bromide—CYP3A4—Doxorubicin—breast cancer	0.00373	0.0109	CbGbCtD
Ipratropium bromide—SLC22A4—mammary gland—breast cancer	0.00142	0.0641	CbGeAlD
Ipratropium bromide—CHRM5—epithelium—breast cancer	0.00112	0.0504	CbGeAlD
Ipratropium bromide—CHRM5—skin of body—breast cancer	0.00106	0.0479	CbGeAlD
Ipratropium bromide—SLC22A5—mammary gland—breast cancer	0.000941	0.0424	CbGeAlD
Ipratropium bromide—SLC22A5—nipple—breast cancer	0.000779	0.0351	CbGeAlD
Ipratropium bromide—SLC22A4—endometrium—breast cancer	0.00071	0.032	CbGeAlD
Ipratropium bromide—SLC22A4—pituitary gland—breast cancer	0.000643	0.029	CbGeAlD
Ipratropium bromide—SLC22A4—adipose tissue—breast cancer	0.00064	0.0288	CbGeAlD
Ipratropium bromide—SLC22A4—female reproductive system—breast cancer	0.000589	0.0265	CbGeAlD
Ipratropium bromide—SLC22A4—adrenal gland—breast cancer	0.000574	0.0259	CbGeAlD
Ipratropium bromide—SLC22A4—bone marrow—breast cancer	0.000556	0.025	CbGeAlD
Ipratropium bromide—CHRM1—female reproductive system—breast cancer	0.000519	0.0234	CbGeAlD
Ipratropium bromide—CHRM3—adipose tissue—breast cancer	0.000506	0.0228	CbGeAlD
Ipratropium bromide—SLC22A5—skin of body—breast cancer	0.000499	0.0225	CbGeAlD
Ipratropium bromide—CHRM2—endocrine gland—breast cancer	0.000483	0.0218	CbGeAlD
Ipratropium bromide—SLC22A5—endometrium—breast cancer	0.00047	0.0212	CbGeAlD
Ipratropium bromide—CHRM3—female reproductive system—breast cancer	0.000465	0.0209	CbGeAlD
Ipratropium bromide—CHRM1—endocrine gland—breast cancer	0.000439	0.0198	CbGeAlD
Ipratropium bromide—SLC22A5—pituitary gland—breast cancer	0.000425	0.0192	CbGeAlD
Ipratropium bromide—SLC22A5—adipose tissue—breast cancer	0.000424	0.0191	CbGeAlD
Ipratropium bromide—CHRM3—female gonad—breast cancer	0.000423	0.0191	CbGeAlD
Ipratropium bromide—CHRM3—endocrine gland—breast cancer	0.000393	0.0177	CbGeAlD
Ipratropium bromide—SLC22A5—female reproductive system—breast cancer	0.000389	0.0175	CbGeAlD
Ipratropium bromide—SLC22A5—adrenal gland—breast cancer	0.00038	0.0171	CbGeAlD
Ipratropium bromide—SLC22A5—female gonad—breast cancer	0.000354	0.016	CbGeAlD
Ipratropium bromide—SLC22A4—lymph node—breast cancer	0.000344	0.0155	CbGeAlD
Ipratropium bromide—CYP3A4—female reproductive system—breast cancer	0.000255	0.0115	CbGeAlD
Ipratropium bromide—CYP2D6—female reproductive system—breast cancer	0.000251	0.0113	CbGeAlD
Ipratropium bromide—Methylphenidate—CYP2D6—breast cancer	0.000247	0.284	CrCbGaD
Ipratropium bromide—Dexmethylphenidate—CYP2D6—breast cancer	0.000247	0.284	CrCbGaD
Ipratropium bromide—CYP2D6—female gonad—breast cancer	0.000229	0.0103	CbGeAlD
Ipratropium bromide—SLC22A5—lymph node—breast cancer	0.000228	0.0103	CbGeAlD
Ipratropium bromide—Trospium—CYP2D6—breast cancer	0.000217	0.25	CrCbGaD
Ipratropium bromide—CYP3A4—endocrine gland—breast cancer	0.000216	0.00974	CbGeAlD
Ipratropium bromide—CYP2D6—endocrine gland—breast cancer	0.000213	0.00958	CbGeAlD
Ipratropium bromide—Scopolamine—ABCB1—breast cancer	0.000158	0.182	CrCbGaD
Ipratropium bromide—Diarrhoea—Gemcitabine—breast cancer	6.34e-05	0.00029	CcSEcCtD
Ipratropium bromide—Infection—Capecitabine—breast cancer	6.33e-05	0.00029	CcSEcCtD
Ipratropium bromide—Neuropathy peripheral—Doxorubicin—breast cancer	6.31e-05	0.000289	CcSEcCtD
Ipratropium bromide—Dizziness—Irinotecan—breast cancer	6.29e-05	0.000288	CcSEcCtD
Ipratropium bromide—Haemoglobin—Epirubicin—breast cancer	6.28e-05	0.000287	CcSEcCtD
Ipratropium bromide—Stomatitis—Doxorubicin—breast cancer	6.27e-05	0.000287	CcSEcCtD
Ipratropium bromide—Rhinitis—Epirubicin—breast cancer	6.26e-05	0.000287	CcSEcCtD
Ipratropium bromide—Urinary tract infection—Doxorubicin—breast cancer	6.26e-05	0.000286	CcSEcCtD
Ipratropium bromide—Conjunctivitis—Doxorubicin—breast cancer	6.26e-05	0.000286	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Capecitabine—breast cancer	6.25e-05	0.000286	CcSEcCtD
Ipratropium bromide—Haemorrhage—Epirubicin—breast cancer	6.24e-05	0.000286	CcSEcCtD
Ipratropium bromide—Eye disorder—Methotrexate—breast cancer	6.24e-05	0.000285	CcSEcCtD
Ipratropium bromide—Diarrhoea—Fluorouracil—breast cancer	6.24e-05	0.000285	CcSEcCtD
Ipratropium bromide—Tinnitus—Methotrexate—breast cancer	6.22e-05	0.000285	CcSEcCtD
Ipratropium bromide—Tachycardia—Capecitabine—breast cancer	6.22e-05	0.000285	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Epirubicin—breast cancer	6.21e-05	0.000284	CcSEcCtD
Ipratropium bromide—Pharyngitis—Epirubicin—breast cancer	6.2e-05	0.000284	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Methotrexate—breast cancer	6.19e-05	0.000284	CcSEcCtD
Ipratropium bromide—Skin disorder—Capecitabine—breast cancer	6.19e-05	0.000283	CcSEcCtD
Ipratropium bromide—Sweating—Doxorubicin—breast cancer	6.17e-05	0.000282	CcSEcCtD
Ipratropium bromide—Urinary tract disorder—Epirubicin—breast cancer	6.17e-05	0.000282	CcSEcCtD
Ipratropium bromide—Urticaria—Paclitaxel—breast cancer	6.17e-05	0.000282	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Capecitabine—breast cancer	6.16e-05	0.000282	CcSEcCtD
Ipratropium bromide—Hypotension—Docetaxel—breast cancer	6.15e-05	0.000281	CcSEcCtD
Ipratropium bromide—Abdominal pain—Paclitaxel—breast cancer	6.13e-05	0.000281	CcSEcCtD
Ipratropium bromide—Urethral disorder—Epirubicin—breast cancer	6.12e-05	0.00028	CcSEcCtD
Ipratropium bromide—Epistaxis—Doxorubicin—breast cancer	6.07e-05	0.000278	CcSEcCtD
Ipratropium bromide—Vomiting—Irinotecan—breast cancer	6.05e-05	0.000277	CcSEcCtD
Ipratropium bromide—Vomiting—Mitoxantrone—breast cancer	6.05e-05	0.000277	CcSEcCtD
Ipratropium bromide—Sinusitis—Doxorubicin—breast cancer	6.04e-05	0.000276	CcSEcCtD
Ipratropium bromide—Immune system disorder—Methotrexate—breast cancer	6.03e-05	0.000276	CcSEcCtD
Ipratropium bromide—Dizziness—Fluorouracil—breast cancer	6.03e-05	0.000276	CcSEcCtD
Ipratropium bromide—Visual impairment—Epirubicin—breast cancer	6.02e-05	0.000275	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Methotrexate—breast cancer	6.01e-05	0.000275	CcSEcCtD
Ipratropium bromide—Rash—Mitoxantrone—breast cancer	6e-05	0.000275	CcSEcCtD
Ipratropium bromide—Rash—Irinotecan—breast cancer	6e-05	0.000275	CcSEcCtD
Ipratropium bromide—Dermatitis—Irinotecan—breast cancer	5.99e-05	0.000274	CcSEcCtD
Ipratropium bromide—Dermatitis—Mitoxantrone—breast cancer	5.99e-05	0.000274	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Docetaxel—breast cancer	5.99e-05	0.000274	CcSEcCtD
Ipratropium bromide—Headache—Mitoxantrone—breast cancer	5.96e-05	0.000273	CcSEcCtD
Ipratropium bromide—Headache—Irinotecan—breast cancer	5.96e-05	0.000273	CcSEcCtD
Ipratropium bromide—Hypotension—Capecitabine—breast cancer	5.95e-05	0.000272	CcSEcCtD
Ipratropium bromide—Insomnia—Docetaxel—breast cancer	5.95e-05	0.000272	CcSEcCtD
Ipratropium bromide—Paraesthesia—Docetaxel—breast cancer	5.91e-05	0.00027	CcSEcCtD
Ipratropium bromide—Vomiting—Gemcitabine—breast cancer	5.89e-05	0.00027	CcSEcCtD
Ipratropium bromide—Dyspnoea—Docetaxel—breast cancer	5.86e-05	0.000268	CcSEcCtD
Ipratropium bromide—Somnolence—Docetaxel—breast cancer	5.85e-05	0.000268	CcSEcCtD
Ipratropium bromide—Rash—Gemcitabine—breast cancer	5.84e-05	0.000268	CcSEcCtD
Ipratropium bromide—Dermatitis—Gemcitabine—breast cancer	5.84e-05	0.000267	CcSEcCtD
Ipratropium bromide—Eye disorder—Epirubicin—breast cancer	5.84e-05	0.000267	CcSEcCtD
Ipratropium bromide—Tinnitus—Epirubicin—breast cancer	5.82e-05	0.000267	CcSEcCtD
Ipratropium bromide—Haemoglobin—Doxorubicin—breast cancer	5.81e-05	0.000266	CcSEcCtD
Ipratropium bromide—Headache—Gemcitabine—breast cancer	5.81e-05	0.000266	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Capecitabine—breast cancer	5.8e-05	0.000266	CcSEcCtD
Ipratropium bromide—Flushing—Epirubicin—breast cancer	5.8e-05	0.000265	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Epirubicin—breast cancer	5.8e-05	0.000265	CcSEcCtD
Ipratropium bromide—Vomiting—Fluorouracil—breast cancer	5.79e-05	0.000265	CcSEcCtD
Ipratropium bromide—Rhinitis—Doxorubicin—breast cancer	5.79e-05	0.000265	CcSEcCtD
Ipratropium bromide—Dyspepsia—Docetaxel—breast cancer	5.79e-05	0.000265	CcSEcCtD
Ipratropium bromide—Haemorrhage—Doxorubicin—breast cancer	5.78e-05	0.000265	CcSEcCtD
Ipratropium bromide—Insomnia—Capecitabine—breast cancer	5.76e-05	0.000264	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Doxorubicin—breast cancer	5.75e-05	0.000263	CcSEcCtD
Ipratropium bromide—Rash—Fluorouracil—breast cancer	5.75e-05	0.000263	CcSEcCtD
Ipratropium bromide—Dermatitis—Fluorouracil—breast cancer	5.74e-05	0.000263	CcSEcCtD
Ipratropium bromide—Pharyngitis—Doxorubicin—breast cancer	5.73e-05	0.000263	CcSEcCtD
Ipratropium bromide—Paraesthesia—Capecitabine—breast cancer	5.72e-05	0.000262	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Paclitaxel—breast cancer	5.72e-05	0.000262	CcSEcCtD
Ipratropium bromide—Headache—Fluorouracil—breast cancer	5.71e-05	0.000261	CcSEcCtD
Ipratropium bromide—Urinary tract disorder—Doxorubicin—breast cancer	5.71e-05	0.000261	CcSEcCtD
Ipratropium bromide—Dysgeusia—Methotrexate—breast cancer	5.69e-05	0.00026	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Docetaxel—breast cancer	5.68e-05	0.00026	CcSEcCtD
Ipratropium bromide—Dyspnoea—Capecitabine—breast cancer	5.68e-05	0.00026	CcSEcCtD
Ipratropium bromide—Fatigue—Docetaxel—breast cancer	5.67e-05	0.00026	CcSEcCtD
Ipratropium bromide—Urethral disorder—Doxorubicin—breast cancer	5.66e-05	0.000259	CcSEcCtD
Ipratropium bromide—Nausea—Mitoxantrone—breast cancer	5.65e-05	0.000259	CcSEcCtD
Ipratropium bromide—Nausea—Irinotecan—breast cancer	5.65e-05	0.000259	CcSEcCtD
Ipratropium bromide—Immune system disorder—Epirubicin—breast cancer	5.64e-05	0.000258	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Epirubicin—breast cancer	5.63e-05	0.000258	CcSEcCtD
Ipratropium bromide—Pain—Docetaxel—breast cancer	5.63e-05	0.000257	CcSEcCtD
Ipratropium bromide—Constipation—Docetaxel—breast cancer	5.63e-05	0.000257	CcSEcCtD
Ipratropium bromide—Back pain—Methotrexate—breast cancer	5.62e-05	0.000257	CcSEcCtD
Ipratropium bromide—Dyspepsia—Capecitabine—breast cancer	5.61e-05	0.000257	CcSEcCtD
Ipratropium bromide—Visual impairment—Doxorubicin—breast cancer	5.57e-05	0.000255	CcSEcCtD
Ipratropium bromide—Asthenia—Paclitaxel—breast cancer	5.57e-05	0.000255	CcSEcCtD
Ipratropium bromide—Nausea—Gemcitabine—breast cancer	5.51e-05	0.000252	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Capecitabine—breast cancer	5.5e-05	0.000252	CcSEcCtD
Ipratropium bromide—Fatigue—Capecitabine—breast cancer	5.49e-05	0.000251	CcSEcCtD
Ipratropium bromide—Pruritus—Paclitaxel—breast cancer	5.49e-05	0.000251	CcSEcCtD
Ipratropium bromide—Vision blurred—Methotrexate—breast cancer	5.47e-05	0.000251	CcSEcCtD
Ipratropium bromide—Constipation—Capecitabine—breast cancer	5.45e-05	0.000249	CcSEcCtD
Ipratropium bromide—Pain—Capecitabine—breast cancer	5.45e-05	0.000249	CcSEcCtD
Ipratropium bromide—Nausea—Fluorouracil—breast cancer	5.41e-05	0.000248	CcSEcCtD
Ipratropium bromide—Eye disorder—Doxorubicin—breast cancer	5.4e-05	0.000247	CcSEcCtD
Ipratropium bromide—Tinnitus—Doxorubicin—breast cancer	5.39e-05	0.000247	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Docetaxel—breast cancer	5.38e-05	0.000246	CcSEcCtD
Ipratropium bromide—Flushing—Doxorubicin—breast cancer	5.36e-05	0.000245	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Doxorubicin—breast cancer	5.36e-05	0.000245	CcSEcCtD
Ipratropium bromide—Flatulence—Epirubicin—breast cancer	5.36e-05	0.000245	CcSEcCtD
Ipratropium bromide—Tension—Epirubicin—breast cancer	5.33e-05	0.000244	CcSEcCtD
Ipratropium bromide—Dysgeusia—Epirubicin—breast cancer	5.32e-05	0.000244	CcSEcCtD
Ipratropium bromide—Diarrhoea—Paclitaxel—breast cancer	5.31e-05	0.000243	CcSEcCtD
Ipratropium bromide—Nervousness—Epirubicin—breast cancer	5.28e-05	0.000242	CcSEcCtD
Ipratropium bromide—Back pain—Epirubicin—breast cancer	5.26e-05	0.000241	CcSEcCtD
Ipratropium bromide—Immune system disorder—Doxorubicin—breast cancer	5.22e-05	0.000239	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Capecitabine—breast cancer	5.21e-05	0.000238	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Doxorubicin—breast cancer	5.21e-05	0.000238	CcSEcCtD
Ipratropium bromide—Abdominal pain—Docetaxel—breast cancer	5.2e-05	0.000238	CcSEcCtD
Ipratropium bromide—Dizziness—Paclitaxel—breast cancer	5.13e-05	0.000235	CcSEcCtD
Ipratropium bromide—Vision blurred—Epirubicin—breast cancer	5.12e-05	0.000235	CcSEcCtD
Ipratropium bromide—Cough—Methotrexate—breast cancer	5.07e-05	0.000232	CcSEcCtD
Ipratropium bromide—Urticaria—Capecitabine—breast cancer	5.06e-05	0.000232	CcSEcCtD
Ipratropium bromide—Abdominal pain—Capecitabine—breast cancer	5.03e-05	0.00023	CcSEcCtD
Ipratropium bromide—Flatulence—Doxorubicin—breast cancer	4.96e-05	0.000227	CcSEcCtD
Ipratropium bromide—Chest pain—Methotrexate—breast cancer	4.95e-05	0.000226	CcSEcCtD
Ipratropium bromide—Myalgia—Methotrexate—breast cancer	4.95e-05	0.000226	CcSEcCtD
Ipratropium bromide—Tension—Doxorubicin—breast cancer	4.94e-05	0.000226	CcSEcCtD
Ipratropium bromide—Vomiting—Paclitaxel—breast cancer	4.93e-05	0.000226	CcSEcCtD
Ipratropium bromide—Dysgeusia—Doxorubicin—breast cancer	4.93e-05	0.000225	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.91e-05	0.000225	CcSEcCtD
Ipratropium bromide—Rash—Paclitaxel—breast cancer	4.89e-05	0.000224	CcSEcCtD
Ipratropium bromide—Dermatitis—Paclitaxel—breast cancer	4.89e-05	0.000224	CcSEcCtD
Ipratropium bromide—Nervousness—Doxorubicin—breast cancer	4.89e-05	0.000224	CcSEcCtD
Ipratropium bromide—Back pain—Doxorubicin—breast cancer	4.87e-05	0.000223	CcSEcCtD
Ipratropium bromide—Headache—Paclitaxel—breast cancer	4.86e-05	0.000223	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Docetaxel—breast cancer	4.85e-05	0.000222	CcSEcCtD
Ipratropium bromide—Palpitations—Epirubicin—breast cancer	4.8e-05	0.00022	CcSEcCtD
Ipratropium bromide—Cough—Epirubicin—breast cancer	4.74e-05	0.000217	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Methotrexate—breast cancer	4.74e-05	0.000217	CcSEcCtD
Ipratropium bromide—Vision blurred—Doxorubicin—breast cancer	4.74e-05	0.000217	CcSEcCtD
Ipratropium bromide—Asthenia—Docetaxel—breast cancer	4.72e-05	0.000216	CcSEcCtD
Ipratropium bromide—Infection—Methotrexate—breast cancer	4.71e-05	0.000216	CcSEcCtD
Ipratropium bromide—Hypertension—Epirubicin—breast cancer	4.69e-05	0.000215	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Capecitabine—breast cancer	4.69e-05	0.000215	CcSEcCtD
Ipratropium bromide—Pruritus—Docetaxel—breast cancer	4.65e-05	0.000213	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Methotrexate—breast cancer	4.65e-05	0.000213	CcSEcCtD
Ipratropium bromide—Myalgia—Epirubicin—breast cancer	4.63e-05	0.000212	CcSEcCtD
Ipratropium bromide—Chest pain—Epirubicin—breast cancer	4.63e-05	0.000212	CcSEcCtD
Ipratropium bromide—Nausea—Paclitaxel—breast cancer	4.61e-05	0.000211	CcSEcCtD
Ipratropium bromide—Skin disorder—Methotrexate—breast cancer	4.61e-05	0.000211	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.6e-05	0.00021	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Methotrexate—breast cancer	4.58e-05	0.00021	CcSEcCtD
Ipratropium bromide—Asthenia—Capecitabine—breast cancer	4.57e-05	0.000209	CcSEcCtD
Ipratropium bromide—Dry mouth—Epirubicin—breast cancer	4.53e-05	0.000207	CcSEcCtD
Ipratropium bromide—Pruritus—Capecitabine—breast cancer	4.51e-05	0.000206	CcSEcCtD
Ipratropium bromide—Diarrhoea—Docetaxel—breast cancer	4.5e-05	0.000206	CcSEcCtD
Ipratropium bromide—Palpitations—Doxorubicin—breast cancer	4.45e-05	0.000203	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Epirubicin—breast cancer	4.44e-05	0.000203	CcSEcCtD
Ipratropium bromide—Oedema—Epirubicin—breast cancer	4.44e-05	0.000203	CcSEcCtD
Ipratropium bromide—Hypotension—Methotrexate—breast cancer	4.43e-05	0.000203	CcSEcCtD
Ipratropium bromide—Infection—Epirubicin—breast cancer	4.41e-05	0.000202	CcSEcCtD
Ipratropium bromide—Cough—Doxorubicin—breast cancer	4.39e-05	0.000201	CcSEcCtD
Ipratropium bromide—Diarrhoea—Capecitabine—breast cancer	4.36e-05	0.000199	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Epirubicin—breast cancer	4.35e-05	0.000199	CcSEcCtD
Ipratropium bromide—Dizziness—Docetaxel—breast cancer	4.35e-05	0.000199	CcSEcCtD
Ipratropium bromide—Hypertension—Doxorubicin—breast cancer	4.34e-05	0.000199	CcSEcCtD
Ipratropium bromide—Tachycardia—Epirubicin—breast cancer	4.33e-05	0.000198	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Methotrexate—breast cancer	4.32e-05	0.000198	CcSEcCtD
Ipratropium bromide—Skin disorder—Epirubicin—breast cancer	4.31e-05	0.000197	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Epirubicin—breast cancer	4.29e-05	0.000196	CcSEcCtD
Ipratropium bromide—Insomnia—Methotrexate—breast cancer	4.29e-05	0.000196	CcSEcCtD
Ipratropium bromide—Chest pain—Doxorubicin—breast cancer	4.28e-05	0.000196	CcSEcCtD
Ipratropium bromide—Myalgia—Doxorubicin—breast cancer	4.28e-05	0.000196	CcSEcCtD
Ipratropium bromide—Paraesthesia—Methotrexate—breast cancer	4.26e-05	0.000195	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.25e-05	0.000195	CcSEcCtD
Ipratropium bromide—Dyspnoea—Methotrexate—breast cancer	4.23e-05	0.000193	CcSEcCtD
Ipratropium bromide—Somnolence—Methotrexate—breast cancer	4.21e-05	0.000193	CcSEcCtD
Ipratropium bromide—Dizziness—Capecitabine—breast cancer	4.21e-05	0.000193	CcSEcCtD
Ipratropium bromide—Dry mouth—Doxorubicin—breast cancer	4.19e-05	0.000192	CcSEcCtD
Ipratropium bromide—Vomiting—Docetaxel—breast cancer	4.18e-05	0.000191	CcSEcCtD
Ipratropium bromide—Dyspepsia—Methotrexate—breast cancer	4.17e-05	0.000191	CcSEcCtD
Ipratropium bromide—Rash—Docetaxel—breast cancer	4.15e-05	0.00019	CcSEcCtD
Ipratropium bromide—Hypotension—Epirubicin—breast cancer	4.15e-05	0.00019	CcSEcCtD
Ipratropium bromide—Dermatitis—Docetaxel—breast cancer	4.14e-05	0.00019	CcSEcCtD
Ipratropium bromide—Headache—Docetaxel—breast cancer	4.12e-05	0.000189	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Doxorubicin—breast cancer	4.11e-05	0.000188	CcSEcCtD
Ipratropium bromide—Oedema—Doxorubicin—breast cancer	4.11e-05	0.000188	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Methotrexate—breast cancer	4.09e-05	0.000187	CcSEcCtD
Ipratropium bromide—Fatigue—Methotrexate—breast cancer	4.09e-05	0.000187	CcSEcCtD
Ipratropium bromide—Infection—Doxorubicin—breast cancer	4.08e-05	0.000187	CcSEcCtD
Ipratropium bromide—Pain—Methotrexate—breast cancer	4.05e-05	0.000186	CcSEcCtD
Ipratropium bromide—Vomiting—Capecitabine—breast cancer	4.05e-05	0.000185	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Epirubicin—breast cancer	4.04e-05	0.000185	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Doxorubicin—breast cancer	4.03e-05	0.000184	CcSEcCtD
Ipratropium bromide—Rash—Capecitabine—breast cancer	4.02e-05	0.000184	CcSEcCtD
Ipratropium bromide—Insomnia—Epirubicin—breast cancer	4.01e-05	0.000184	CcSEcCtD
Ipratropium bromide—Dermatitis—Capecitabine—breast cancer	4.01e-05	0.000184	CcSEcCtD
Ipratropium bromide—Tachycardia—Doxorubicin—breast cancer	4.01e-05	0.000183	CcSEcCtD
Ipratropium bromide—Headache—Capecitabine—breast cancer	3.99e-05	0.000183	CcSEcCtD
Ipratropium bromide—Skin disorder—Doxorubicin—breast cancer	3.99e-05	0.000183	CcSEcCtD
Ipratropium bromide—Paraesthesia—Epirubicin—breast cancer	3.98e-05	0.000182	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Doxorubicin—breast cancer	3.97e-05	0.000182	CcSEcCtD
Ipratropium bromide—Dyspnoea—Epirubicin—breast cancer	3.96e-05	0.000181	CcSEcCtD
Ipratropium bromide—Somnolence—Epirubicin—breast cancer	3.94e-05	0.000181	CcSEcCtD
Ipratropium bromide—Nausea—Docetaxel—breast cancer	3.91e-05	0.000179	CcSEcCtD
Ipratropium bromide—Dyspepsia—Epirubicin—breast cancer	3.91e-05	0.000179	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Methotrexate—breast cancer	3.88e-05	0.000177	CcSEcCtD
Ipratropium bromide—Hypotension—Doxorubicin—breast cancer	3.84e-05	0.000176	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Epirubicin—breast cancer	3.83e-05	0.000175	CcSEcCtD
Ipratropium bromide—Fatigue—Epirubicin—breast cancer	3.83e-05	0.000175	CcSEcCtD
Ipratropium bromide—Constipation—Epirubicin—breast cancer	3.79e-05	0.000174	CcSEcCtD
Ipratropium bromide—Pain—Epirubicin—breast cancer	3.79e-05	0.000174	CcSEcCtD
Ipratropium bromide—Nausea—Capecitabine—breast cancer	3.78e-05	0.000173	CcSEcCtD
Ipratropium bromide—Urticaria—Methotrexate—breast cancer	3.77e-05	0.000172	CcSEcCtD
Ipratropium bromide—Abdominal pain—Methotrexate—breast cancer	3.75e-05	0.000172	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.74e-05	0.000171	CcSEcCtD
Ipratropium bromide—Insomnia—Doxorubicin—breast cancer	3.71e-05	0.00017	CcSEcCtD
Ipratropium bromide—Paraesthesia—Doxorubicin—breast cancer	3.69e-05	0.000169	CcSEcCtD
Ipratropium bromide—Dyspnoea—Doxorubicin—breast cancer	3.66e-05	0.000168	CcSEcCtD
Ipratropium bromide—Somnolence—Doxorubicin—breast cancer	3.65e-05	0.000167	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Epirubicin—breast cancer	3.63e-05	0.000166	CcSEcCtD
Ipratropium bromide—Dyspepsia—Doxorubicin—breast cancer	3.61e-05	0.000165	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Doxorubicin—breast cancer	3.54e-05	0.000162	CcSEcCtD
Ipratropium bromide—Fatigue—Doxorubicin—breast cancer	3.54e-05	0.000162	CcSEcCtD
Ipratropium bromide—Urticaria—Epirubicin—breast cancer	3.52e-05	0.000161	CcSEcCtD
Ipratropium bromide—Constipation—Doxorubicin—breast cancer	3.51e-05	0.000161	CcSEcCtD
Ipratropium bromide—Pain—Doxorubicin—breast cancer	3.51e-05	0.000161	CcSEcCtD
Ipratropium bromide—Abdominal pain—Epirubicin—breast cancer	3.51e-05	0.000161	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Methotrexate—breast cancer	3.49e-05	0.00016	CcSEcCtD
Ipratropium bromide—Asthenia—Methotrexate—breast cancer	3.4e-05	0.000156	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Doxorubicin—breast cancer	3.36e-05	0.000154	CcSEcCtD
Ipratropium bromide—Pruritus—Methotrexate—breast cancer	3.35e-05	0.000154	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Epirubicin—breast cancer	3.27e-05	0.00015	CcSEcCtD
Ipratropium bromide—Urticaria—Doxorubicin—breast cancer	3.26e-05	0.000149	CcSEcCtD
Ipratropium bromide—Abdominal pain—Doxorubicin—breast cancer	3.25e-05	0.000149	CcSEcCtD
Ipratropium bromide—Diarrhoea—Methotrexate—breast cancer	3.24e-05	0.000148	CcSEcCtD
Ipratropium bromide—Asthenia—Epirubicin—breast cancer	3.18e-05	0.000146	CcSEcCtD
Ipratropium bromide—Pruritus—Epirubicin—breast cancer	3.14e-05	0.000144	CcSEcCtD
Ipratropium bromide—Dizziness—Methotrexate—breast cancer	3.14e-05	0.000144	CcSEcCtD
Ipratropium bromide—Diarrhoea—Epirubicin—breast cancer	3.04e-05	0.000139	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Doxorubicin—breast cancer	3.02e-05	0.000138	CcSEcCtD
Ipratropium bromide—Vomiting—Methotrexate—breast cancer	3.01e-05	0.000138	CcSEcCtD
Ipratropium bromide—Rash—Methotrexate—breast cancer	2.99e-05	0.000137	CcSEcCtD
Ipratropium bromide—Dermatitis—Methotrexate—breast cancer	2.99e-05	0.000137	CcSEcCtD
Ipratropium bromide—Headache—Methotrexate—breast cancer	2.97e-05	0.000136	CcSEcCtD
Ipratropium bromide—Asthenia—Doxorubicin—breast cancer	2.95e-05	0.000135	CcSEcCtD
Ipratropium bromide—Dizziness—Epirubicin—breast cancer	2.93e-05	0.000134	CcSEcCtD
Ipratropium bromide—Pruritus—Doxorubicin—breast cancer	2.9e-05	0.000133	CcSEcCtD
Ipratropium bromide—Vomiting—Epirubicin—breast cancer	2.82e-05	0.000129	CcSEcCtD
Ipratropium bromide—Nausea—Methotrexate—breast cancer	2.82e-05	0.000129	CcSEcCtD
Ipratropium bromide—Diarrhoea—Doxorubicin—breast cancer	2.81e-05	0.000129	CcSEcCtD
Ipratropium bromide—Rash—Epirubicin—breast cancer	2.8e-05	0.000128	CcSEcCtD
Ipratropium bromide—Dermatitis—Epirubicin—breast cancer	2.79e-05	0.000128	CcSEcCtD
Ipratropium bromide—Headache—Epirubicin—breast cancer	2.78e-05	0.000127	CcSEcCtD
Ipratropium bromide—Dizziness—Doxorubicin—breast cancer	2.71e-05	0.000124	CcSEcCtD
Ipratropium bromide—Nausea—Epirubicin—breast cancer	2.64e-05	0.000121	CcSEcCtD
Ipratropium bromide—Vomiting—Doxorubicin—breast cancer	2.61e-05	0.000119	CcSEcCtD
Ipratropium bromide—Rash—Doxorubicin—breast cancer	2.59e-05	0.000118	CcSEcCtD
Ipratropium bromide—Dermatitis—Doxorubicin—breast cancer	2.59e-05	0.000118	CcSEcCtD
Ipratropium bromide—Headache—Doxorubicin—breast cancer	2.57e-05	0.000118	CcSEcCtD
Ipratropium bromide—Nausea—Doxorubicin—breast cancer	2.44e-05	0.000112	CcSEcCtD
Ipratropium bromide—CHRM3—Metabolism—ALB—breast cancer	4.68e-06	5.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NFKBIA—breast cancer	4.67e-06	5.87e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—FN1—breast cancer	4.66e-06	5.87e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—HMOX1—breast cancer	4.66e-06	5.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NFKBIA—breast cancer	4.65e-06	5.85e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ITPR1—breast cancer	4.65e-06	5.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NOTCH1—breast cancer	4.62e-06	5.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CDKN1B—breast cancer	4.62e-06	5.81e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NOTCH1—breast cancer	4.61e-06	5.8e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NFKBIA—breast cancer	4.61e-06	5.8e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HPGDS—breast cancer	4.59e-06	5.78e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR downstream signaling—AKT1—breast cancer	4.57e-06	5.75e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HBA1—breast cancer	4.56e-06	5.74e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NOTCH1—breast cancer	4.56e-06	5.74e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CASP3—breast cancer	4.53e-06	5.69e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—APC—breast cancer	4.52e-06	5.69e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CG—breast cancer	4.52e-06	5.69e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—KIT—breast cancer	4.52e-06	5.69e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—IL2—breast cancer	4.52e-06	5.69e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—KIT—breast cancer	4.51e-06	5.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CG—breast cancer	4.51e-06	5.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—APC—breast cancer	4.51e-06	5.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—IL6—breast cancer	4.5e-06	5.66e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—NOS3—breast cancer	4.47e-06	5.63e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ABCB1—breast cancer	4.47e-06	5.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—EGF—breast cancer	4.47e-06	5.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—KIT—breast cancer	4.46e-06	5.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CG—breast cancer	4.46e-06	5.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—APC—breast cancer	4.46e-06	5.62e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTT1—breast cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ACHE—breast cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—EGF—breast cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—EGF—breast cancer	4.41e-06	5.55e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CCND1—breast cancer	4.41e-06	5.54e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—JUN—breast cancer	4.4e-06	5.53e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—TYMS—breast cancer	4.39e-06	5.52e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CTNNB1—breast cancer	4.36e-06	5.49e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—GSTM1—breast cancer	4.34e-06	5.46e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—NCOR1—breast cancer	4.34e-06	5.46e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.34e-06	5.46e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—MAPK3—breast cancer	4.33e-06	5.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—MAPK3—breast cancer	4.32e-06	5.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MMP9—breast cancer	4.28e-06	5.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—MAPK3—breast cancer	4.27e-06	5.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CDKN1A—breast cancer	4.26e-06	5.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—PTEN—breast cancer	4.25e-06	5.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—BRAF—breast cancer	4.25e-06	5.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—BRAF—breast cancer	4.24e-06	5.33e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYP17A1—breast cancer	4.22e-06	5.31e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—BRAF—breast cancer	4.2e-06	5.28e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ENO1—breast cancer	4.18e-06	5.25e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PTGS1—breast cancer	4.18e-06	5.25e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MAPK8—breast cancer	4.16e-06	5.23e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—GPX1—breast cancer	4.16e-06	5.23e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—AKT1—breast cancer	4.15e-06	5.22e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IGF1—breast cancer	4.14e-06	5.21e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—AKT2—breast cancer	4.14e-06	5.2e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3CB—breast cancer	4.13e-06	5.2e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IGF1—breast cancer	4.13e-06	5.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—AKT2—breast cancer	4.12e-06	5.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—EGFR—breast cancer	4.12e-06	5.18e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—CYP1A1—breast cancer	4.12e-06	5.18e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—EGFR—breast cancer	4.11e-06	5.17e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYP2D6—breast cancer	4.09e-06	5.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PTGS2—breast cancer	4.09e-06	5.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IGF1—breast cancer	4.09e-06	5.14e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—AKT2—breast cancer	4.08e-06	5.14e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ERCC2—breast cancer	4.08e-06	5.13e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—EGFR—breast cancer	4.07e-06	5.12e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NCOA2—breast cancer	4.02e-06	5.06e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CD—breast cancer	3.98e-06	5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CD—breast cancer	3.96e-06	4.98e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—SRC—breast cancer	3.94e-06	4.96e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—SERPINE1—breast cancer	3.93e-06	4.95e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	3.92e-06	4.94e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CD—breast cancer	3.92e-06	4.94e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—SERPINE1—breast cancer	3.92e-06	4.93e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—FASN—breast cancer	3.9e-06	4.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—KRAS—breast cancer	3.89e-06	4.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	3.89e-06	4.89e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—BCHE—breast cancer	3.88e-06	4.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—SERPINE1—breast cancer	3.88e-06	4.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—KRAS—breast cancer	3.88e-06	4.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—KRAS—breast cancer	3.84e-06	4.83e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—VEGFA—breast cancer	3.84e-06	4.83e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—MTHFR—breast cancer	3.84e-06	4.83e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—SLC5A5—breast cancer	3.83e-06	4.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—STAT3—breast cancer	3.8e-06	4.78e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NOS3—breast cancer	3.75e-06	4.72e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NOS3—breast cancer	3.74e-06	4.71e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NOS3—breast cancer	3.71e-06	4.66e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—SLC2A1—breast cancer	3.7e-06	4.66e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NQO1—breast cancer	3.7e-06	4.66e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MAPK3—breast cancer	3.63e-06	4.57e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	3.58e-06	4.5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PTEN—breast cancer	3.57e-06	4.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	3.56e-06	4.48e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MDM2—breast cancer	3.56e-06	4.48e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYP1B1—breast cancer	3.55e-06	4.47e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MDM2—breast cancer	3.55e-06	4.47e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—RAF1—breast cancer	3.55e-06	4.46e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—CAV1—breast cancer	3.54e-06	4.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—RAF1—breast cancer	3.54e-06	4.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MYC—breast cancer	3.53e-06	4.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—RELA—breast cancer	3.53e-06	4.44e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	3.53e-06	4.44e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—TGFB1—breast cancer	3.53e-06	4.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—RELA—breast cancer	3.52e-06	4.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MDM2—breast cancer	3.52e-06	4.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—ERBB2—breast cancer	3.51e-06	4.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—RAF1—breast cancer	3.5e-06	4.41e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—ERBB2—breast cancer	3.5e-06	4.4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—RELA—breast cancer	3.49e-06	4.39e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.48e-06	4.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—ERBB2—breast cancer	3.47e-06	4.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CB—breast cancer	3.46e-06	4.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MTOR—breast cancer	3.46e-06	4.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—EGFR—breast cancer	3.46e-06	4.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CB—breast cancer	3.45e-06	4.34e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MTOR—breast cancer	3.45e-06	4.34e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MTOR—breast cancer	3.42e-06	4.3e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CB—breast cancer	3.42e-06	4.3e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NCOA1—breast cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—STK11—breast cancer	3.34e-06	4.2e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYP19A1—breast cancer	3.34e-06	4.2e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CXCL8—breast cancer	3.33e-06	4.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CXCL8—breast cancer	3.32e-06	4.18e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—HRAS—breast cancer	3.31e-06	4.16e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—HRAS—breast cancer	3.3e-06	4.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CXCL8—breast cancer	3.29e-06	4.13e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—HRAS—breast cancer	3.27e-06	4.11e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—KRAS—breast cancer	3.27e-06	4.11e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CDKN1B—breast cancer	3.25e-06	4.09e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CDKN1B—breast cancer	3.24e-06	4.08e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CG—breast cancer	3.22e-06	4.05e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—AKT1—breast cancer	3.22e-06	4.05e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CDKN1B—breast cancer	3.21e-06	4.04e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—AKT1—breast cancer	3.21e-06	4.03e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CASP3—breast cancer	3.19e-06	4.01e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IL2—breast cancer	3.18e-06	4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CASP3—breast cancer	3.18e-06	4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—AKT1—breast cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IL2—breast cancer	3.17e-06	3.99e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—IL6—breast cancer	3.17e-06	3.98e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—IL6—breast cancer	3.16e-06	3.97e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CASP3—breast cancer	3.15e-06	3.96e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IL2—breast cancer	3.14e-06	3.95e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—IL6—breast cancer	3.13e-06	3.93e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—COMT—breast cancer	3.1e-06	3.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CCND1—breast cancer	3.1e-06	3.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—JUN—breast cancer	3.1e-06	3.89e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CCND1—breast cancer	3.09e-06	3.89e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTP1—breast cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—JUN—breast cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CTNNB1—breast cancer	3.07e-06	3.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CTNNB1—breast cancer	3.06e-06	3.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CCND1—breast cancer	3.06e-06	3.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—JUN—breast cancer	3.06e-06	3.84e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HMOX1—breast cancer	3.05e-06	3.83e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ITPR1—breast cancer	3.04e-06	3.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CTNNB1—breast cancer	3.03e-06	3.81e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MMP9—breast cancer	3.01e-06	3.79e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MMP9—breast cancer	3e-06	3.78e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CDKN1A—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—PIK3CA—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PTEN—breast cancer	2.99e-06	3.77e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CDKN1A—breast cancer	2.99e-06	3.76e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PTEN—breast cancer	2.98e-06	3.75e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MMP9—breast cancer	2.97e-06	3.74e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CDKN1A—breast cancer	2.96e-06	3.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PTEN—breast cancer	2.96e-06	3.72e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAPK8—breast cancer	2.93e-06	3.68e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ABCB1—breast cancer	2.92e-06	3.68e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—AKT1—breast cancer	2.92e-06	3.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAPK8—breast cancer	2.92e-06	3.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—AKT1—breast cancer	2.91e-06	3.66e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—TP53—breast cancer	2.9e-06	3.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAPK8—breast cancer	2.89e-06	3.64e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—AKT1—breast cancer	2.88e-06	3.63e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—TYMS—breast cancer	2.87e-06	3.61e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.84e-06	3.57e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NCOR1—breast cancer	2.84e-06	3.57e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTM1—breast cancer	2.84e-06	3.57e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CD—breast cancer	2.83e-06	3.56e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ALB—breast cancer	2.8e-06	3.52e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—SRC—breast cancer	2.78e-06	3.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—HRAS—breast cancer	2.78e-06	3.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—SRC—breast cancer	2.77e-06	3.48e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—SRC—breast cancer	2.74e-06	3.45e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GPX1—breast cancer	2.72e-06	3.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—VEGFA—breast cancer	2.7e-06	3.4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—VEGFA—breast cancer	2.7e-06	3.39e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYP1A1—breast cancer	2.69e-06	3.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—STAT3—breast cancer	2.68e-06	3.37e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—NOS3—breast cancer	2.68e-06	3.37e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—VEGFA—breast cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—STAT3—breast cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ERCC2—breast cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—IL6—breast cancer	2.66e-06	3.34e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—STAT3—breast cancer	2.64e-06	3.33e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAPK3—breast cancer	2.56e-06	3.22e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAPK3—breast cancer	2.55e-06	3.21e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAPK3—breast cancer	2.53e-06	3.18e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3CA—breast cancer	2.52e-06	3.17e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—MTHFR—breast cancer	2.51e-06	3.16e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MYC—breast cancer	2.49e-06	3.13e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—TGFB1—breast cancer	2.48e-06	3.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MYC—breast cancer	2.48e-06	3.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—TGFB1—breast cancer	2.47e-06	3.11e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CB—breast cancer	2.47e-06	3.11e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MYC—breast cancer	2.46e-06	3.09e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—AKT1—breast cancer	2.45e-06	3.08e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—TGFB1—breast cancer	2.45e-06	3.08e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PTGS2—breast cancer	2.45e-06	3.08e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—EGFR—breast cancer	2.43e-06	3.06e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—EGFR—breast cancer	2.43e-06	3.05e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—EGFR—breast cancer	2.4e-06	3.02e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CAV1—breast cancer	2.31e-06	2.91e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—KRAS—breast cancer	2.3e-06	2.89e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—KRAS—breast cancer	2.29e-06	2.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—KRAS—breast cancer	2.27e-06	2.85e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PTEN—breast cancer	2.13e-06	2.68e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CA—breast cancer	2.11e-06	2.66e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CG—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CA—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CA—breast cancer	2.09e-06	2.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—AKT1—breast cancer	2.06e-06	2.59e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—TP53—breast cancer	2.04e-06	2.57e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—TP53—breast cancer	2.04e-06	2.56e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—TP53—breast cancer	2.02e-06	2.54e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—HRAS—breast cancer	1.95e-06	2.46e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—HRAS—breast cancer	1.95e-06	2.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—HRAS—breast cancer	1.93e-06	2.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IL6—breast cancer	1.87e-06	2.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IL6—breast cancer	1.86e-06	2.35e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CD—breast cancer	1.85e-06	2.33e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IL6—breast cancer	1.85e-06	2.32e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ALB—breast cancer	1.83e-06	2.3e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NOS3—breast cancer	1.75e-06	2.2e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—AKT1—breast cancer	1.73e-06	2.17e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—AKT1—breast cancer	1.72e-06	2.16e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—AKT1—breast cancer	1.7e-06	2.14e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CB—breast cancer	1.61e-06	2.03e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PTGS2—breast cancer	1.6e-06	2.01e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CA—breast cancer	1.51e-06	1.89e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PTEN—breast cancer	1.4e-06	1.76e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—AKT1—breast cancer	1.23e-06	1.55e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CA—breast cancer	9.84e-07	1.24e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—AKT1—breast cancer	8.04e-07	1.01e-05	CbGpPWpGaD
